McCune-Albright Syndrome
This clinical trial will evaluate how the drug fulvestrant affects girls with progressive precocious puberty associated with McCune Albright Syndrome (MAS). Girls younger than 11 with a diagnosis of progressive precocious puberty before the age of eight who have not received prior treatment for the condition with fulvestrant may be eligible.

The research sites are located across the United States.

More information
Please see http://www.centerwatch.com/patient/studies/cat260.html.

Happy Holidays!

Melanie Wong
Executive Director
National Adrenal Diseases Foundation (NADF)
505 Northern Blvd., Suite 200
Great Neck, NY 11021
(516) 487-4992
NADFMAIL@aol.com
www.medhelp.org/nadf

NADF does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical knowledge. In all cases, NADF recommends that you consult your own physician regarding any course of treatment or medication.

Please help raise money for NADF by searching the Internet with GoodSearch powered by Yahoo!